作者
Marta Moreno, Aissata Barry, Markus Gmeiner, Jean Baptist Yaro, Samuel S Sermé, Isabel Byrne, Jordache Ramjith, Alphonse Ouedraogo, Issiaka Soulama, Lynn Grignard, Seyi Soremekun, Simon Koele, Rob ter Heine, Amidou Z Ouedraogo, Jean Sawadogo, Edith Sanogo, Issa N Ouedraogo, Denise Hien, Sodiomon Bienvenu Sirima, John Bradley, Teun Bousema, Chris Drakeley, Alfred B Tiono
发表日期
2024
期刊
BMJ Open
卷号
14
期号
3
出版商
BMJ Publishing Group
简介
Introduction Seasonal malaria chemoprevention (SMC) involves repeated administrations of sulfadoxinepyrimethamine plus amodiaquine to children below the age of 5 years during the peak transmission season in areas of seasonal malaria transmission. While highly impactful in reducing Plasmodium falciparum malaria burden in controlled research settings, the impact of SMC on infection prevalence is moderate in real-life settings. It remains unclear what drives this efficacy decay. Recently, the WHO widened the scope for SMC to target all vulnerable populations. The Ministry of Health (MoH) in Burkina Faso is considering extending SMC to children below 10 years old. We aim to assess the impact of SMC on clinical incidence and parasite prevalence and quantify the human infectious reservoir for malaria in this population. Methods and analysis We will perform a cluster randomised trial in Saponé Health …
学术搜索中的文章
M Moreno, A Barry, M Gmeiner, JB Yaro, SS Sermé… - BMJ Open, 2024